Cargando…

How Well Do Results From Randomized Clinical Trials and/or Recommendations for Implantable Cardioverter‐Defibrillator Programming Diffuse Into Clinical Practice?: Translation Assessed in a National Cohort of Patients With Implantable Cardioverter‐Defibrillators (ALTITUDE)

BACKGROUND: Inappropriate implantable cardioverter‐defibrillator programming can be detrimental. Whether trials/recommendations informing best implantable cardioverter‐defibrillator programming (high‐rate cutoff and/or extended duration of detection) influence practice is unknown. METHODS AND RESULT...

Descripción completa

Detalles Bibliográficos
Autores principales: Varma, Niraj, Jones, Paul, Wold, Nicholas, Cronin, Edmond, Stein, Kenneth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405582/
https://www.ncbi.nlm.nih.gov/pubmed/30712432
http://dx.doi.org/10.1161/JAHA.117.007392
_version_ 1783401104520773632
author Varma, Niraj
Jones, Paul
Wold, Nicholas
Cronin, Edmond
Stein, Kenneth
author_facet Varma, Niraj
Jones, Paul
Wold, Nicholas
Cronin, Edmond
Stein, Kenneth
author_sort Varma, Niraj
collection PubMed
description BACKGROUND: Inappropriate implantable cardioverter‐defibrillator programming can be detrimental. Whether trials/recommendations informing best implantable cardioverter‐defibrillator programming (high‐rate cutoff and/or extended duration of detection) influence practice is unknown. METHODS AND RESULTS: We measured reaction to publication of MADIT‐RIT (Multicenter Automatic Defibrillator Implantation Trial–Reduce Inappropriate Therapy; 2012) and the Consensus Statement (2015) providing generic programming parameters, in a national cohort of implantable cardioverter‐defibrillator recipients, using the ALTITUDE database (Boston Scientific). Yearly changes in programmed parameters to either trial‐specified or class 1 recommended parameters (≥185 beats per minute or delay ≥6 seconds) were assessed in parallel. From 2008 to 2017, 232 982 patients (aged 67±13 years; 28% women) were analyzed. Prevalence of MADIT‐RIT–specific settings before publication was <1%, increasing to 13.6% in the year following. Thereafter, this increased by <6% over 5 years. Among preexisting implants (91 171), most patients (58 739 [64.4%]) underwent at least 1 in‐person device reprogramming after trial publication, but <2% were reprogrammed to MADIT‐RIT settings. Notably, prevalence of programming to ≥185 beats per minute or delay ≥6 seconds was increased by MADIT‐RIT (57.4% in 2013 versus 40.2% at baseline), but the following publication of recommendations had minor incremental effect (73.2% in 2016 versus 70.8% in 2015). High‐rate cutoff programming was favored almost 2‐fold compared with extended duration throughout the test period. Practice changes demonstrated large interhospital and interstate variations. CONCLUSIONS: Trial publication had an immediate effect during 1 year postpublication, but absolute penetration was low, and amplified little with time. Consensus recommendations had a negligible effect. However, generic programming was exercised more widely, and increased after trial publication, but not following recommendations.
format Online
Article
Text
id pubmed-6405582
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-64055822019-03-21 How Well Do Results From Randomized Clinical Trials and/or Recommendations for Implantable Cardioverter‐Defibrillator Programming Diffuse Into Clinical Practice?: Translation Assessed in a National Cohort of Patients With Implantable Cardioverter‐Defibrillators (ALTITUDE) Varma, Niraj Jones, Paul Wold, Nicholas Cronin, Edmond Stein, Kenneth J Am Heart Assoc Original Research BACKGROUND: Inappropriate implantable cardioverter‐defibrillator programming can be detrimental. Whether trials/recommendations informing best implantable cardioverter‐defibrillator programming (high‐rate cutoff and/or extended duration of detection) influence practice is unknown. METHODS AND RESULTS: We measured reaction to publication of MADIT‐RIT (Multicenter Automatic Defibrillator Implantation Trial–Reduce Inappropriate Therapy; 2012) and the Consensus Statement (2015) providing generic programming parameters, in a national cohort of implantable cardioverter‐defibrillator recipients, using the ALTITUDE database (Boston Scientific). Yearly changes in programmed parameters to either trial‐specified or class 1 recommended parameters (≥185 beats per minute or delay ≥6 seconds) were assessed in parallel. From 2008 to 2017, 232 982 patients (aged 67±13 years; 28% women) were analyzed. Prevalence of MADIT‐RIT–specific settings before publication was <1%, increasing to 13.6% in the year following. Thereafter, this increased by <6% over 5 years. Among preexisting implants (91 171), most patients (58 739 [64.4%]) underwent at least 1 in‐person device reprogramming after trial publication, but <2% were reprogrammed to MADIT‐RIT settings. Notably, prevalence of programming to ≥185 beats per minute or delay ≥6 seconds was increased by MADIT‐RIT (57.4% in 2013 versus 40.2% at baseline), but the following publication of recommendations had minor incremental effect (73.2% in 2016 versus 70.8% in 2015). High‐rate cutoff programming was favored almost 2‐fold compared with extended duration throughout the test period. Practice changes demonstrated large interhospital and interstate variations. CONCLUSIONS: Trial publication had an immediate effect during 1 year postpublication, but absolute penetration was low, and amplified little with time. Consensus recommendations had a negligible effect. However, generic programming was exercised more widely, and increased after trial publication, but not following recommendations. John Wiley and Sons Inc. 2019-02-03 /pmc/articles/PMC6405582/ /pubmed/30712432 http://dx.doi.org/10.1161/JAHA.117.007392 Text en © 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Varma, Niraj
Jones, Paul
Wold, Nicholas
Cronin, Edmond
Stein, Kenneth
How Well Do Results From Randomized Clinical Trials and/or Recommendations for Implantable Cardioverter‐Defibrillator Programming Diffuse Into Clinical Practice?: Translation Assessed in a National Cohort of Patients With Implantable Cardioverter‐Defibrillators (ALTITUDE)
title How Well Do Results From Randomized Clinical Trials and/or Recommendations for Implantable Cardioverter‐Defibrillator Programming Diffuse Into Clinical Practice?: Translation Assessed in a National Cohort of Patients With Implantable Cardioverter‐Defibrillators (ALTITUDE)
title_full How Well Do Results From Randomized Clinical Trials and/or Recommendations for Implantable Cardioverter‐Defibrillator Programming Diffuse Into Clinical Practice?: Translation Assessed in a National Cohort of Patients With Implantable Cardioverter‐Defibrillators (ALTITUDE)
title_fullStr How Well Do Results From Randomized Clinical Trials and/or Recommendations for Implantable Cardioverter‐Defibrillator Programming Diffuse Into Clinical Practice?: Translation Assessed in a National Cohort of Patients With Implantable Cardioverter‐Defibrillators (ALTITUDE)
title_full_unstemmed How Well Do Results From Randomized Clinical Trials and/or Recommendations for Implantable Cardioverter‐Defibrillator Programming Diffuse Into Clinical Practice?: Translation Assessed in a National Cohort of Patients With Implantable Cardioverter‐Defibrillators (ALTITUDE)
title_short How Well Do Results From Randomized Clinical Trials and/or Recommendations for Implantable Cardioverter‐Defibrillator Programming Diffuse Into Clinical Practice?: Translation Assessed in a National Cohort of Patients With Implantable Cardioverter‐Defibrillators (ALTITUDE)
title_sort how well do results from randomized clinical trials and/or recommendations for implantable cardioverter‐defibrillator programming diffuse into clinical practice?: translation assessed in a national cohort of patients with implantable cardioverter‐defibrillators (altitude)
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405582/
https://www.ncbi.nlm.nih.gov/pubmed/30712432
http://dx.doi.org/10.1161/JAHA.117.007392
work_keys_str_mv AT varmaniraj howwelldoresultsfromrandomizedclinicaltrialsandorrecommendationsforimplantablecardioverterdefibrillatorprogrammingdiffuseintoclinicalpracticetranslationassessedinanationalcohortofpatientswithimplantablecardioverterdefibrillatorsaltitude
AT jonespaul howwelldoresultsfromrandomizedclinicaltrialsandorrecommendationsforimplantablecardioverterdefibrillatorprogrammingdiffuseintoclinicalpracticetranslationassessedinanationalcohortofpatientswithimplantablecardioverterdefibrillatorsaltitude
AT woldnicholas howwelldoresultsfromrandomizedclinicaltrialsandorrecommendationsforimplantablecardioverterdefibrillatorprogrammingdiffuseintoclinicalpracticetranslationassessedinanationalcohortofpatientswithimplantablecardioverterdefibrillatorsaltitude
AT croninedmond howwelldoresultsfromrandomizedclinicaltrialsandorrecommendationsforimplantablecardioverterdefibrillatorprogrammingdiffuseintoclinicalpracticetranslationassessedinanationalcohortofpatientswithimplantablecardioverterdefibrillatorsaltitude
AT steinkenneth howwelldoresultsfromrandomizedclinicaltrialsandorrecommendationsforimplantablecardioverterdefibrillatorprogrammingdiffuseintoclinicalpracticetranslationassessedinanationalcohortofpatientswithimplantablecardioverterdefibrillatorsaltitude